<DOC>
	<DOC>NCT02622022</DOC>
	<brief_summary>36 patients with interstitial lung disease will be randomized to 1 weeks treatment with morphine hydrochloride as oral linctus 5 mg, four times a day, and 5 mg as needed up to 4 times a day, or corresponding doses of placebo. VAS score for dyspnea will be evaluated after 1 hour and 1 week at follow up. Other questionnaires will also be evaluated (GAD-7, K-BUILD, Leicester score)</brief_summary>
	<brief_title>Palliation of Dyspnea With Morphine in Patients With Interstitial Lung Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Dyspnea</mesh_term>
	<mesh_term>Lung Diseases, Interstitial</mesh_term>
	<mesh_term>Morphine</mesh_term>
	<criteria>A diagnosis of interstitial lung disease (IPF, NSIP, RAILS, SclILS, MCTDILS, asbestous, drug induced ILD, unclassified ILD) Dyspnea corresponding to Medial Research Councils (MRC) dyspnea score ≥ 3 Written consent Age ≥ 18 years Competent For fertile women: Negative pregnancy test For fertile and sexually active participants: Use of safe anticonceptionals Ongoing infection Decreased lung function to a degree which makes any form of respiratory depression life threatening Treatment with morphine or morphine analogues Allergy towards morphine hydrochloride</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>110 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>randomised</keyword>
	<keyword>placebo controlled</keyword>
	<keyword>clinical trial</keyword>
</DOC>